NASDAQ : CING

Cingulate Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 4.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 72.42M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Details

NameCingulate Inc.
SectorHealthcare
IndustryBiotechnology
Employees14
Founded2012
Ipo Date2021-12-08
CeoShane Schaffer
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price6.00
IsinUS17248W3034
Cusip17248W303
Cik1862150
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Shane J. Schaffer Pharm.D.Co-Founder, Chief Executive Officer and Chairman of the Board
Dr. Matthew N. Brams M.D.Co-Founder, Executive Vice President and Chief Medical Officer
Jennifer L. Callahan CPAExecutive Vice President, Chief Financial Officer and Secretary
Dr. Raul R. Silva M.D.Co-Founder, Executive Vice President and Chief Science Officer
Thomas DaltonVice President of Investor and Public Relations
Downey Bryan WadeExecutive Vice President and Chief Commercial Officer

Contact

Address1901 West 47th Place, Kansas City, Kansas 66205, United States
Phone913 942 2300
Websitehttps://www.cingulate.com